The emergence of liquid biopsy using circulating tumor cells (CTCs) as a resource to identify genomic alterations in cancer presents new opportunities for diagnosis, therapy, and surveillance. We identified EML4-ALK gene rearrangement in expanded CTCs from a patient with ALK-positive lung adenocarcinoma. At the time of radiographic progression, CTCs obtained from the patient revealed a drug resistance mutation (i.e., L1196M on the ALK gene). CTCs were expanded ex vivo and drug sensitivity testing was performed using two ALK inhibitors, crizotinib and ceritinib. The half maximal inhibitory concentration of ceritinib was 1664 nM compared with crizotinib (2268 nM), showing that ceritinib was a more potent ALK inhibitor. We show that it is feasible to detect serial genetic alterations in expanded CTCs and perform in vitro drug screening. These findings support the clinical utility of CTCs not only for diagnosis, but also a potential tool for drug sensitivity testing in distinct subsets of lung cancer and for personalized precision medicine.
Introduction
Advances in sequencing have shifted the landscape of NSCLC therapy to a personalized approach that is driven by molecular alterations in each patient's tumor, leading to improved survival for a small minority of patients. Three percent to 7% of patients with NSCLC have tumors that contain an inversion in chromosome 2 that juxtaposes the 5 0 end of the echinoderm microtubuleassociated protein-like 4 (EML4) gene with the 3 0 end of the anaplastic lymphoma kinase (ALK) gene, resulting in the novel fusion oncogene EML4-ALK.
1 Therapy in this group of patients with a specific tyrosine kinase inhibitor, crizotinib, resulted in rapid responses (<6 weeks), greater response rates (65%), and longer progressionfree survival (7.7 months), compared with chemotherapy. 2 However, most patients with ALK-positive lung cancer who respond to crizotinib undergo a relapse within months (range 3.8-21 months) because of the emergence of resistance mechanisms. 3 Among the various resistance mechanisms, gatekeeper mutation in the ALK gene (L1196M) is identified in 9% of patients. 4 The second-line inhibitor, ceritinib, overcomes this crizotinib-resistant mutation. More recently, third-generation ALK inhibitors *Corresponding author.
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with improved half maximal inhibitory concentration (IC50) targeting wild-type EML4-ALK and resistance mutations are in clinical trials, including PF-06463922. 5 To enhance treatment response, it is imperative to identify the most effective tyrosine kinase inhibitor at the outset and to identify, by longitudinal testing, the emergence of resistance that typifies the molecular evolution of these driver oncogene-mediated cancers. At the current time, the practice is to biopsy and rebiopsy at the time of clinical/radiographic progression, which is invasive and not without risk. ALK rearrangement is identified through fluorescence in situ hybridization (FISH) using a break-apart probe. 6 A separation of a red and a green signal indicates gene rearrangement. In recent years, EML4-ALK rearrangement has been detected in circulating tumor cells (CTCs) from peripheral blood of patients with NSCLC. 7, 8 CTCs can be expanded ex vivo for genotyping and drug testing, as shown in patients with breast and colon cancers. 9, 10 We present a patient with advanced stage NSCLC harboring an EML4-ALK rearrangement in the tumor. CTCs were isolated from the peripheral blood of this patient during three clinical visits. The cells were expanded through a microfluidic co-culture model that was reported in our previous study. 11 We found concordant ALK rearrangement and secondary resistance mutation L1196M in the CTCs similar to that in the tumor. Drug testing with crizotinib and ceritinib was also performed on the expanded CTCs.
Materials and Methods

CTC Isolation and Expansion
Five milliliters of peripheral blood was drawn from the lung cancer patient into purple top ethylenediaminetetraacetic acid tubes during each visit. Blood was drawn at University of Michigan Hospital under an institutional review board-approved protocol. CTCs were captured with a cocktail of antibodies against EpCAM and CD44 in three CTC capture devices and cultured with cancer-associated fibroblasts (CAFs) in the devices for 2 weeks and then outside devices for 1 month. The detailed procedure can be found in our previous study.
11
FISH Analysis on CTCs
CTCs were spun onto polylysine-coated slides and fixed with 1:3 acetic acid and methanol followed by airdrying. FISH test with two-color and break-apart probes were performed on the slides. The probes used were green 5 0 ALK probe (RP11-993C21) and red 3 0 ALK probe (RP11-984I21). Colocalizing red and green signals indicated normal chromosomes, and separate red and green signals indicated ALK rearrangement. All images were captured under 100Â oil immersion objective using Zeiss Axioplan microscope (Carl Zeiss, Oberkochen, Germany) equipped with CCD camera. Captured images were processed using In situ Imaging System software (Metasystems, Germany). 
Drug Testing
One thousand CTCs, CAFs, A549, or H3122 cells were plated in each well on a 96-well plate. Each drug concentration had wells in triplicate. Six different concentrations were tested for each drug. Cells were incubated with drugs for 72 hours. After treatment, each well was incubated with Cell Proliferation Reagent WST-1 assay (Roche, Mannheim, Germany). Absorbance was measured with a Biotek-Synergy Neo-Plate Reader (BioTek Instruments, Winooski, VT). IC50s were determined by nonlinear regression model using Prism software (GraphPad Software, San Diego, CA).
Results
Primary Tumor Mutation Status
A 42-year-old man with a history of stage IV Hodgkin's lymphoma was found to have metastatic lung adenocarcinoma on restaging scans (Fig. 1A) . Biopsy specimens of the lung mass and FISH revealed ALK gene rearrangement (Fig. 1B) . The patient was initially placed on crizotinib. A computed tomography scan 4 months after crizotinib treatment revealed near complete resolution of disease. However, a scan at 7 months showed progression in the right hilum (Fig. 1A) . The patient underwent a bronchoscopy and rebiopsy of the hilar mass. Whole-exome sequencing (70-100Â coverage) of the biopsy revealed a secondary mutation (i.e., L1196M) and resultant resistance to crizotinib. He was then treated with ceritinib and his repeat computed tomography scans revealed a marked decrease in the hilar mass. The patient underwent serial magnetic resonance imaging (MRI) scans of the brain. At the time of first disease progression-2 months before the start of ceritinib treatment-the MRI scan of the brain was negative. The next brain imaging occurred when he experienced neurologic symptoms. The patient then had regular brain surveillance with MRI. After 11 months, the patient had a progression of disease with brain metastasis in addition to progression in right lower lobe and right hilum. Whole-exome sequencing of the biopsy of brain metastasis revealed wild-type EML4-ALK and an absence of L1196M mutation. ALK amplification and alternative oncogenic drivers were not detected in the brain biopsy. Table 1 summarizes the mutation status of the tumor at three clinical visits.
Detecting ALK Rearrangement in Expanded CTCs
In parallel, we isolated and expanded CTCs from his blood at the time of initial diagnosis, at the time he developed resistance to crizotinib, and then at the time of brain metastasis. FISH analysis identified ALK rearrangement in expanded CTCs (Fig. 2) . At initial diagnosis, 83 cells were counted, 15 cells had one copy, six cells had two copies, and four cells had three or more copies of ALK (30% cells positive). At the time the patient developed resistance to crizotinib, 54 cells were counted, five cells had one copy and three cells had two copies of ALK (15% cells positive). When the patient developed brain metastasis, 86 cells were counted, 10 cells had one copy, two cells had two copies, and two cells had three or more copies of ALK (16% cells positive). The criteria for ALK positivity is 15% or more cells containing separated signals with 50 or more cells counted. 12 Accordingly, CTCs were positive for ALK rearrangement at all three time points, concordant with findings on tumor biopsy specimens (Table 2) .
Identifying L1196M Mutation in Expanded CTCs
After examining ALK positivity, we performed Sanger sequencing to detect L1196M mutation on the ALK gene. It was found that the gatekeeper mutation emerged in the expanded CTC when the patient developed resistance to crizotinib and had radiographic progression. The L1196M mutation disappeared from expanded CTCs collected at the time of brain metastasis, which again mirrored the findings from the brain biopsy ( Fig. 2 ; Table 2 ).
Drug Testing on Expanded CTCs
After verifying the mutational status of expanded CTCs, we performed in vitro experiments to test CTCs collected and cultured at the initial visit against crizotinib and ceritinib. The CTCs were admixed with CAFs, so we also conducted control experiments on pure CAFs, A549 (i.e., resistant negative control), and H3122 (ALKrearranged, sensitive positive control for crizotinib and ceritinib) cell lines. The IC50s for the two compounds using the expanded ALK rearranged CTCs are shown in Figure 3 . The IC50 values for crizotinib and ceritinib were 2268 nM and 1664 nM, respectively.
Discussion
We previously reported a three-dimensional microfluidic co-culture model for expanding small number of CTCs in patients with lung cancer. 11 The present study shows that expanded CTCs carry ALK rearrangements and that the dynamic detection of drug-resistant mutations by analyzing CTCs longitudinally is possible. The emergence and disappearance of L1196M mutation likely reflects the clonal evolution of tumor cells toward drug resistance against crizotinib and ceritinib. Through expansion of CTCs, drug-susceptibility testing was enabled, offering unique advantages over serum markers and circulating cell-free nucleic acids.
Uniquely, we show the feasibility of performing drug testing on expanded lung CTCs, which is a challenge because of the small number of cells. Performing drug screening by isolating CTCs from peripheral blood is meaningful because it is less invasive than obtaining solid tumor biopsy specimens and is also more accessible. In this study, the IC50 for crizotinib was higher than ceritinib (2268 nM versus 1664 nM), as reported by others. 4 These values were higher than reported IC50s against the H3122 cell line, likely because of the presence of CAFs. However, the ratio of IC50 favored ceritinib as the more potent ALK inhibitor against ALKrearranged CTCs.
Personalized drug testing predicts therapeutic responses, especially in patients with lung cancer. It was reported that 64% of driver mutations were detected in patients with lung adenocarcinoma, of which nearly 30% were selected for targeted therapies. 13 It is imperative to monitor acquired mutations that render targeted therapies ineffective early in disease progression. CTCs as a "liquid biopsy" can potentially serve as drug testing platforms to guide therapeutic selection.
